Regenxbio (RGNX) Payables (2014 - 2025)

Regenxbio's Payables history runs 12 years deep, the most recent figure standing at $21.4 million for Q4 2025.

• On a quarterly basis, Payables fell 6.32% year-over-year to $21.4 million in Q4 2025; TTM through Dec 2025 was $21.4 million, a 6.32% decrease from a year earlier, with the FY2025 full-year figure at $21.4 million, down 6.32% from the prior year.
• Payables retreated to $21.4 million in Q4 2025 per RGNX's latest filing, from $22.3 million in the prior quarter.
• Across five years, Payables topped out at $31.4 million in Q1 2024 and bottomed at $9.4 million in Q2 2021.
• The 5-year median for Payables is $21.5 million (2025), against an average of $20.0 million.
• Across the five-year window, Payables jumped 138.98% in 2022 and slumped 39.27% in 2025, its largest moves.
• Year by year, Payables stood at $11.4 million in 2021, then jumped by 138.98% to $27.2 million in 2022, then slipped by 16.27% to $22.8 million in 2023, then rose by 0.05% to $22.8 million in 2024, then declined by 6.32% to $21.4 million in 2025.
• Per Business Quant, the three latest RGNX Payables figures stand at $21.4 million (Q4 2025), $22.3 million (Q3 2025), and $21.7 million (Q2 2025).